Investment Thesis
Celonis SE (CLON.DE) is the undisputed leader in process mining and execution management, a critical layer in enterprise automation. The company’s platform helps organizations discover inefficiencies, automate workflows, and optimize operations in real time. With a growing total addressable market (TAM) estimated at $60B+ and a sticky customer base including 40% of the Fortune 500, Celonis is well-positioned to benefit from the secular trend of business automation.
12-Month Catalysts
- Product Expansion: Launch of Celonis EMS (Execution Management System) with AI-driven process optimization and automation capabilities, driving higher deal sizes and upsell opportunities.
- Profitability Inflection: Management guided for positive free cash flow by Q4 2025, with improving gross margins (targeting 75%+) and operating leverage from scale.
- Strategic Partnerships: Deepening integrations with SAP, Salesforce, and ServiceNow, expanding distribution and accelerating enterprise adoption.
- IPO or Listing Upgrade: Potential move to the Frankfurt Stock Exchange’s Prime Standard or a US listing, increasing visibility and liquidity.
Key Risks
- Competition: Incumbents like SAP (with Signavio) and Microsoft (Power Automate) could erode market share.
- Macro Slowdown: Enterprises may delay large automation projects in a recession, impacting new bookings.
Valuation Summary
Celonis trades at an enterprise value of ~€8B, implying a revenue multiple of ~8x on 2025 estimated sales of €1B. This is a discount to high-growth peers like UiPath (10x) and ServiceNow (12x), despite similar growth rates (30%+). As profitability improves, multiple expansion to 12x could yield 50% upside.
Balance Sheet Summary
Celonis has a strong balance sheet with over €1.5B in cash and no debt, providing ample runway to invest in growth and weather any downturn.
Disclaimer: This is not financial advice. Investing involves risk, including loss of principal. Past performance does not guarantee future results.